Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 24, 2024Open Access

Experience of tertiary prophylaxis with extended half-life factor prophylaxis in India

View Full Paper
Ask AI
Bookmark
Share

Authors

APArchit PandharipandeNRNita RadhakrishnanSVShruti Verma

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pandharipande et al. (2024) studied this question.

synapsesocial.com/papers/68e5b13eb6db64358754a8d7https://doi.org/10.22541/au.172449974.46711866/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Use of Extended Half-Life Factor IX in Children with Haemophilia B2025
  2. 2Changes in Quality of Life, Adherence, and Kinesiophobia in Patients with Hemophilia Treated with Extended Half-Life Treatment: Final Results of the LongHest Project2024 · 5 citations
  3. 3Extended Half-Life Factor Concentrates in Haemophilia Treatment2026 · 1 citations
  4. 4Changes over the last two decades in Hemophilia A and B management in a Tertiary Care Pediatric Centre.2024 · 2 citations
  5. 5Tailored prophylaxis in severe hemophilia A: Real-world experience with efanesoctocog alfa2025